Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 12, 2014, Pages 1671-1680

  Tuttle, R Michael ^a   Haddad, Robert I ^b   Ball, Douglas W ^c   Byrd, David ^d   Dickson, Paxton ^e   Duh, Quan Yang ^f   Ehya, Hormoz ^g   Haymart, Megan ^h   Hoh, Carl ⁱ   Hunt, Jason P ^j   Iagaru, Andrei ^k   Kandeel, Fouad ^l   Kopp, Peter ^m   Lamonica, Dominick M ⁿ   Lydiatt, William M ^o   McCaffrey, Judith ^p   Moley, Jeffrey F ^q   Parks, Lee ^r   Raeburn, Christopher D ^s   Ridge, John A ^g   Ringel, Matthew D ^t   Scheri, Randall P ^u   Shah, Jatin P ^a   Sherman, Steven I ^v   Sturgeon, Cord ^m   Waguespack, Steven G ^v   Wang, Thomas N ^w   Wirth, Lori J ^x   Hoffmann, Karin G ^y   Hughes, Miranda ^y   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ ROSWELL PARK CANCER INSTITUTE   (United States)

^o UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q BARNES JEWISH HOSPITAL   (United States)

^r VANDERBILT INGRAM CANCER CENTER   (United States)

^s University of Colorado Cancer Center   (United States)

^t OHIO STATE UNIVERSITY   (United States)

^u DUKE CANCER INSTITUTE   (United States)

^v UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^w UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^x MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^y National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; DACARBAZINE; DENOSUMAB; DOXORUBICIN; LENVATINIB; LEVOTHYROXINE; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; SUNITINIB; THYROTROPIN; VANDETANIB; VEMURAFENIB; ANILIDE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ACCREDITATION; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTINUING EDUCATION; DIFFERENTIATED THYROID CANCER; DRUG FATALITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INTERPERSONAL COMMUNICATION; LIVER TOXICITY; PATIENT SELECTION; PRACTICE GUIDELINE; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; METASTASIS; PATHOLOGY; THYROID NEOPLASMS;

ADENOCARCINOMA; ANILIDES; GUIDELINES AS TOPIC; HUMANS; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS;

EID: 84918790948     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0169     Document Type: Article

References (87)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Available at: Http://seer.cancer.gov/csr/1975-2011/.
4. Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511.
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
6. Sacks W, Braunstein GD. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract 2014; 20: 263-275.
7. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014; 2: 356-358.
8. Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2009; 73: 795-801.
9. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 2005; 63: 418-427.
10. Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009; 74: 1083-1091.
11. Chow SM, Yau S, Kwan CK, et al. Local and regional control in patients with papillary thyroid carcinoma: Specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 2006; 13: 1159-1172.
12. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer 2006; 13: 971-977.
13. Bernet V, Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs 2014; 19: 225-241.
14. Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: A systematic literature review. Thyroid 2013; 23: 392-407.
15. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010; 22: 464-468.
16. Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol 2012; 29: 1421-1428.
17. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. Tumori 1990; 76: 480-483.
18. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987; 10: 303-310.
19. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553-559.
20. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623-632.
21. Bales SR, Chopra IJ. Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res 2011; 2011: 102636.
22. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: A new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011; 7: 617-624.
23. Kapiteijn E, Schneider TC, Morreau H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23: 10-18.
24. Perez CA, Santos ES, Arango BA, et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012; 34: 736-745.
25. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-328.
26. Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-Term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial. Eur J Endocrinol 2012; 167: 643-650.
27. Massicotte MH, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: A retrospective study of the TUTHYREF network. Eur J Endocrinol 2014; 170: 575-582.
28. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161: 923-931.
29. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95: 2588-2595.
30. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684.
31. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
32. Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: A systematic review. Oncologist 2014; 19: 251-258.
33. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16: 5260-5268.
34. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905.
35. Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014; 120: 2694-2703.
36. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008; 26: 4708-4713.
37. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010; 11: 962-972.
38. Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013; 23: 1277-1283.
39. Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) [abstract]. J Clin Oncol 2014; 2014: Abstract LBA6008.
40. Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014; 99: 2086-2094.
41. Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: Specific role of lenvatinib. Biologics 2014; 8: 129-139.
42. Ball DW, Sherman SI, Jarzab B, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response [abstract]. J Clin Oncol 2012; 30(Suppl 15): Abstract 5518.
43. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol 2011; 24(Suppl 2): S44-52.
44. Tuttle RM, Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 2007; 5: 641-646.
45. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 713-722.
46. Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf 2014; 13: 723-733.
47. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058-1069.
48. Eaby-Sandy B, Grande C, Viale PH. Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors. J Adv Pract Oncol 2012; 3: 138-150.
49. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011; 2011: 985780.
50. Sideras K, Menefee ME, Burton JK, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-Targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010; 28: E312-313.
51. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: A clinician's perspective. Semin Oncol 2014; 41(Suppl 2): S1-16.
52. Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7(Suppl 1): S5-21; quiz S22-24.
53. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: A clinical perspective. Lancet Oncol 2014; 15: E315-326.
54. McFarland DC, Misiukiewicz KJ. Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer. Onco Targets Ther 2014; 7: 1291-1299.
55. Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013; 98: 31-42.
56. Cohen AB, Brose MS. Second-line treatment for advanced thyroid cancer: An indication in need of randomized clinical trials. J Clin Endocrinol Metab 2014; 99: 1995-1997.
57. Owonikoko TK, Chowdry RP, Chen Z, et al. Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. Oncologist 2013; 18: 1262-1269.
58. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.
59. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012; 18: 3722-3730.
60. Traynor K. Cabozantinib approved for advanced medullary thyroid cancer. Am J Health Syst Pharm 2013; 70: 88.
61. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639-3646.
62. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
63. Haddad RI. How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. J Clin Oncol 2013; 31: 3618-3620.
64. Aleman JO, Farooki A, Girotra M. Effects of tyrosine kinase inhibition on bone metabolism: Untargeted consequences of targeted therapies. Endocr Relat Cancer 2014; 21: R247-259.
65. Schlumberger M, Bastholt L, Dralle H, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 2012; 1: 5-14.
66. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 2013; 49: 707-710.
67. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660-2666.
68. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2664-2671.
69. Grande E, Kreissl MC, Filetti S, et al. Vandetanib in advanced medullary thyroid cancer: Review of adverse event management strategies. Adv Ther 2013; 30: 945-966.
70. Lacouture ME, Ciccolini K, Kloos RT, Agulnik M. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid 2014; 24: 1329-1340.
71. Haraldsdottir S, Shah MH. An update on clinical trials of targeted therapies in thyroid cancer. Curr Opin Oncol 2014; 26: 36-44.
72. Viola D, Cappagli V, Elisei R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol 2013; 9: 1083-1092.
73. Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 2000; 83: 715-718.
74. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995; 71: 363-365.
75. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
76. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-Term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
77. Vitale G, Fonderico F, Martignetti A, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001; 84: 1586-1590.
78. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323-2330.
79. De Souza JA, Busaidy N, Zimrin A, et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC) [abstract]. J Clin Oncol 2010; 28(Suppl 15): Abstract 5504.
80. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol 2007; 25(Suppl 18): Abstract 14065.
81. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008; 148: 567.
82. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94: 1493-1499.
83. Hong D, Ye L, Gagel R, et al. Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008; 7: 1001-1006.
84. Spector E, Franklin MJ, Truskinovsky AM, Dudek AZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol 2010; 49: 104-106.
85. Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol 2010; 28: E390-392.
86. Bugalho MJ, Domingues R, Borges A. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. Oncologist 2009; 14: 1083-1087.
87. Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014; 99: 1687-1693.